Dazodalibep is a CD40 ligand antagonist recently investigated in a phase 2 double-blind trial for the treatment of active moderate-severe rheumatoid arthritis (RA) with inadequate response to disease-modifying anti-rheumatic drugs (NCT04163991). We were delighted to speak to Dr. Alan J. Kivitz (Altoona Center for Clinical Research, Duncansville, PA, USA) to discuss the rationale for investigating dazodalibep in RA and the findings from the phase 2 study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs.‘ (Abstract number: 2008) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What are the limitations of current disease-modifying anti-rheumatic drugs?
- What is dazodalibep and what is the rationale for its use in patients with rheumatoid arthritis?
- What were the eligibility criteria of your phase 2 study?
- What were the primary and secondary endpoints and how well were they achieved?
- On the basis of current findings, what is the potential of dazodalibep in the treatment paradigm for rheumatoid arthritis?
Disclosures: Alan J. Kivitz has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
